Cole A T, Hawkey C J
Department of Therapeutics, University Hospital, Nottingham.
Br J Hosp Med. 1992;47(8):581-90.
Salicylates and steroids remain the mainstay of treatment for inflammatory bowel disease. New formulations which attempt to lower the rates of side effects are under evaluation. The value of azathioprine has been established in ulcerative colitis and cyclosporin has been shown to be of value. Dietary therapy in Crohn's disease has been the focus of a large amount of research and benefits have been demonstrated. New therapies including bioengineered drugs are anticipated.
水杨酸盐和类固醇仍然是炎症性肠病治疗的主要手段。旨在降低副作用发生率的新制剂正在评估中。硫唑嘌呤在溃疡性结肠炎中的价值已得到确立，环孢素也已证明有价值。克罗恩病的饮食疗法一直是大量研究的重点，并且已证明有好处。预计会有包括生物工程药物在内的新疗法。
